Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01896323 | CC-223 and Ketoconazole Drug-Drug Interaction Study | PHASE1 | COMPLETED | 14 | — | — | Jul 1, 2013 | Aug 1, 2013 | Nov 12, 2019 | - | — |
AUC-area under the plasma concentration-time curve;
| Arm | Type | Description |
|---|---|---|
| CC-223 | EXPERIMENTAL | CC-223 administration on study day 1 of Period 1 and study day 5 of Period 2 |
| Ketokonazole | ACTIVE_COMPARATOR | Ketoconazole administration on study days 1 through 8 of Period 2 |
| Name | Type | Description |
|---|---|---|
| CC-223 | DRUG | CC-223 20 mg tablets |
| Ketoconazole | DRUG | Ketoconazole 400 mg tablets |
Inclusion Criteria: 1. Must understand and voluntarily sign a written informed consent form before participation. 2. Must be able to communicate with the study doctor, understand and comply with the requirements of the study, and agree to adhere to restrictions and examination schedules. 3. Healthy...